Identify the leading healthcare trends in Latin America. With information on Brazil, Mexico, Colombia, Chile, Peru, Argentina. Pharmaceuticals and Hospitals, as well as hospital demographics.
Connected health, also known as technology-enabled care (TEC), involves the convergence of health technology, digital media, and mobile devices. It enables patients, carers, and healthcare professionals (HCPs) to access data and information more easily and improve the quality and outcomes of both health and social care.
DELOITTE: 2017 Global Health Sciences Outlook Report - A global perspective on the healthcare industry and its strategic sectors. Deloitte efficiently delivers an uncomplicated but in-depth look at worldwide healthcare. Rising demand and associated spending are being fueled by an aging population; the growing prevalence of chronic diseases and comorbidities; development of costly clinical innovations; increasing patient awareness, knowledge, and expectations; and continued economic uncertainty despite regional pockets of recovery are just a few of the key issues and trends impacting the global health care sector.
Connect with me at LinkedIn and Twitter, visit my healthcare website -an industry resource since 2004...
Twitter: @johngbaresky
LinkedIn: https://www.linkedin.com/in/johngbaresky
My website: www.healthcaremedicalpharmaceuticaldirectory.com
John Baresky Healthcare Marketing Leader, Pharmaceutical Marketing, Digital Marketing Strategy, Content Marketing Strategy, Market Access Strategy, Healthcare RPA Software Marketing Strategy
Technology has the power to improve access to healthcare services, especially for people with mobility problems. Mobile technology can empower patients and carers by giving them more control over their health and making them less dependent on HCPs for health information.
Healthcare in future will not be like today. The changes are dramatic and paradigmatic. In this presentation we will see some the mega trends influencing this field. Future Trends, Population Increase, Aging, Urbanization, Individualization and health awareness, Consumerism, Shifting Economy, Technological Progress, Climate Change and Environmental Pollution, Shifting Disease Patterns, lifestyle diseases, high-calorie diet, physical inactivity and higher levels of stress, Decline in muscular, skeletal and infectious diseases, Better-informed Patients, Decline in information asymmetry, Internet, Social Networks, Self care, home care, self-medication, New Health Markets, Pharma, economy, pharmerging countries, Growing Competition, Brand, Generic, Innovative, HighTech, Increasing Cost Pressure, Aging, Better Access, Complex Supply Chains, R&D outsourcing, Complex Products, supply chains, Product Development, Innovation, Pharmacogenomics, Therapeutic Vaccines, Regenerative medicine, 3D Printing, Robot-assisted surgeries, Mobile health,Tele-medical applications, Direct-to-consumer (DTC ) distribution, Direct-to-consumer (DTC ) advertisement, OTC Growth, home delivery, prescription drugs,
Brazil's economy has grew at over 15% per year for a decade and is now waking up to a harsh reality.
Social unrest, corruption scandals, political changes and rising inflation will shape growth moving forward.
What does this mean for the Healthcare sector? How will the government react? What does this mean for the private sector and particularly for foreign investors?
Fragmented private care
Recent developments and outlook
Foreign investments and Consolidations
Private hospital income & expenditure
Trends & Outlook
Connected health, also known as technology-enabled care (TEC), involves the convergence of health technology, digital media, and mobile devices. It enables patients, carers, and healthcare professionals (HCPs) to access data and information more easily and improve the quality and outcomes of both health and social care.
DELOITTE: 2017 Global Health Sciences Outlook Report - A global perspective on the healthcare industry and its strategic sectors. Deloitte efficiently delivers an uncomplicated but in-depth look at worldwide healthcare. Rising demand and associated spending are being fueled by an aging population; the growing prevalence of chronic diseases and comorbidities; development of costly clinical innovations; increasing patient awareness, knowledge, and expectations; and continued economic uncertainty despite regional pockets of recovery are just a few of the key issues and trends impacting the global health care sector.
Connect with me at LinkedIn and Twitter, visit my healthcare website -an industry resource since 2004...
Twitter: @johngbaresky
LinkedIn: https://www.linkedin.com/in/johngbaresky
My website: www.healthcaremedicalpharmaceuticaldirectory.com
John Baresky Healthcare Marketing Leader, Pharmaceutical Marketing, Digital Marketing Strategy, Content Marketing Strategy, Market Access Strategy, Healthcare RPA Software Marketing Strategy
Technology has the power to improve access to healthcare services, especially for people with mobility problems. Mobile technology can empower patients and carers by giving them more control over their health and making them less dependent on HCPs for health information.
Healthcare in future will not be like today. The changes are dramatic and paradigmatic. In this presentation we will see some the mega trends influencing this field. Future Trends, Population Increase, Aging, Urbanization, Individualization and health awareness, Consumerism, Shifting Economy, Technological Progress, Climate Change and Environmental Pollution, Shifting Disease Patterns, lifestyle diseases, high-calorie diet, physical inactivity and higher levels of stress, Decline in muscular, skeletal and infectious diseases, Better-informed Patients, Decline in information asymmetry, Internet, Social Networks, Self care, home care, self-medication, New Health Markets, Pharma, economy, pharmerging countries, Growing Competition, Brand, Generic, Innovative, HighTech, Increasing Cost Pressure, Aging, Better Access, Complex Supply Chains, R&D outsourcing, Complex Products, supply chains, Product Development, Innovation, Pharmacogenomics, Therapeutic Vaccines, Regenerative medicine, 3D Printing, Robot-assisted surgeries, Mobile health,Tele-medical applications, Direct-to-consumer (DTC ) distribution, Direct-to-consumer (DTC ) advertisement, OTC Growth, home delivery, prescription drugs,
Brazil's economy has grew at over 15% per year for a decade and is now waking up to a harsh reality.
Social unrest, corruption scandals, political changes and rising inflation will shape growth moving forward.
What does this mean for the Healthcare sector? How will the government react? What does this mean for the private sector and particularly for foreign investors?
Fragmented private care
Recent developments and outlook
Foreign investments and Consolidations
Private hospital income & expenditure
Trends & Outlook
he technologies collectively known as health information technology (health IT) share a common attribute: they enable the secure collection and exchange of vast amounts of health data about individuals. The collection and movement of this data will power the health care of the future. Health IT has the potential to empower individuals and increase transparency; enhance the ability to study care delivery and payment systems; and ultimately achieve improvements in care, efficiency, and population health.
Medical second opinion market Size, Share, Growth Business Strategy and Forec...jitendra more
Increasing number of errors in medical billing is also one of the prominent factors responsible for the growth of the market. For instance,according to a study published by the Medical Billing Advocates of America in2019, an estimated 80.0% of medical bills contain at least one error. Further,problems in medical billing errors cost a total of ~US$ 210 billion each year in the US. These possibilities and occurrences of financial errors areprojected to accelerate the growth of the medical second opinion market by 2027.
Increased competition from generics, a growing pressure from payers to reduce costs, and a market in which a drug’s success is more closely tied to its performance are transforming the pharmaceutical and life sciences industry. As the healthcare industry transitions from treating existing illnesses to taking steps to prevent illness before it occurs. By leveraging technology and information traditional pharma business is adding value beyond the pill and emphasizing the need of strong partnerships and strategic alliances with the broader ecosystem
IPHA Healthcare Facts and Figures provides detailed facts and figures about healthcare in Ireland and the pharmaceutical and healthcare industry both nationally and globally across the following areas: Healthcare Today, Self-Care Today, Demographic Trends, Healthcare Tomorrow, The Medicines Industry, Medicines in the Community and Medicines and Global Health
Sanofi Digital Transformation and Self Medication_mHealth IsraelLevi Shapiro
Presentation by Dr. Caty Ebel Bitoun, Global Medical Digital Transformation Head, Sanofi, for the mHealth Israel community, April 12, 2021. Begins with an overview and description of Sanofi worldwide. Explanatio of Sanofi's three Global Business Units (GBU) focused on prioritized portfolio. 1st GBU is Specialty Care: Immunology, Rare Diseases / Rare Blood Disorders, Neurology / Multiple Sclerosis, Oncology; 2nd GBU is General Medicines: Diabetes, Cardiovascular, Established Products; 3rd GBU is Vaccines: Influenza vaccines, Polio Pertussis & Hib, Boosters, Meningitis, others. There is also a standalone GBU for Consumer Healthcare: Allergy, Cough & Cold, Pain, Digestive Health, Mental Wellness. Digital is changing the healthcare landscape. Empowering patients / consumers and organising self monitoring. Digital improves patient information and product usage with sustainibility value proposition. Digital Therapeutics are opening a new way to manage pain. Sanofi Ideal partner profile has Mature technology
including mature business model. Scalable across more than 2
geographies. Compliance with cybersecurity and data protection. Sustainibility value proposition. Easy to purchase
(onsite & e-commerce). Impact on consumers includes Consumer focus. Proven improvement in health or lifestyle outcome. Data driven claims supported by scientific evidence. Augmented consumer experience. Sanofi has a partner centric philosophy.
Successfully Accessing Medical Equipment Markets in CIVETS Available on Rese...QYResearchReports
The short-lived positron-emitting isotopes used in PET imaging are generally produced in a cyclotron and then synthesised on-site before patient administration. Although not requiring the use of a nuclear reactor, this limits the use of PET imaging to centres with access to a cyclotron and synthesis equipment. Therefore, a major development is the recent availability of smaller and cheaper cyclotrons which are designed to produce C-11 and F-18 isotopes economically and on-demand, without the need for radiochemistry or PET accelerator expertise.
The 10 companies booming in healthcare sector smallinsightscare
Development is a continuous process in any sector. It brings in more comfort, more precision, and more enhanced way of living.Acknowledging the remarkable contribution of the leading companies in the care sector, we bring to you the special issue of “The 10 Companies Booming in Healthcare Sector”.
'The Digital Healthcare Leap' highlights insights into how digital health could be an answer to the emerging markets’ challenge to achieve sustainable growth; and leapfrog the developed nations to provide quality, affordable, universal and patient-centric care.
With increased internet and smartphone penetration, and the arrival of new affordable technological solutions in the market, digital healthcare will eventually become a fundamental business imperative. The challenge to healthcare providers for the future, is to adapt and set strategies that leverage new technology while putting patients at the heart of everything they do.
Healthcare as an industry is transforming. The concept of wellbeing is increasing in importance. Living environments are evolving, including smart homes, assisted living and robotics. Technologies and innovations are having major impacts to individual’s life. Individuals are taking more control and recognizing also their responsibility.
Business Finland and Future Watch commissioned a study on the landscape of developments that will impact the delivery of Health & Wellbeing, to better understand the anticipated transformations, impacts and opportunities to support its strategy for ensuring Finland is well positioned to take advantage of such trends and to help drive better decision making for all stakeholders in Finland. Results of the study are published and discussed with stakeholders and companies in Business Finland’s Smart Life Finland program webinars.
he technologies collectively known as health information technology (health IT) share a common attribute: they enable the secure collection and exchange of vast amounts of health data about individuals. The collection and movement of this data will power the health care of the future. Health IT has the potential to empower individuals and increase transparency; enhance the ability to study care delivery and payment systems; and ultimately achieve improvements in care, efficiency, and population health.
Medical second opinion market Size, Share, Growth Business Strategy and Forec...jitendra more
Increasing number of errors in medical billing is also one of the prominent factors responsible for the growth of the market. For instance,according to a study published by the Medical Billing Advocates of America in2019, an estimated 80.0% of medical bills contain at least one error. Further,problems in medical billing errors cost a total of ~US$ 210 billion each year in the US. These possibilities and occurrences of financial errors areprojected to accelerate the growth of the medical second opinion market by 2027.
Increased competition from generics, a growing pressure from payers to reduce costs, and a market in which a drug’s success is more closely tied to its performance are transforming the pharmaceutical and life sciences industry. As the healthcare industry transitions from treating existing illnesses to taking steps to prevent illness before it occurs. By leveraging technology and information traditional pharma business is adding value beyond the pill and emphasizing the need of strong partnerships and strategic alliances with the broader ecosystem
IPHA Healthcare Facts and Figures provides detailed facts and figures about healthcare in Ireland and the pharmaceutical and healthcare industry both nationally and globally across the following areas: Healthcare Today, Self-Care Today, Demographic Trends, Healthcare Tomorrow, The Medicines Industry, Medicines in the Community and Medicines and Global Health
Sanofi Digital Transformation and Self Medication_mHealth IsraelLevi Shapiro
Presentation by Dr. Caty Ebel Bitoun, Global Medical Digital Transformation Head, Sanofi, for the mHealth Israel community, April 12, 2021. Begins with an overview and description of Sanofi worldwide. Explanatio of Sanofi's three Global Business Units (GBU) focused on prioritized portfolio. 1st GBU is Specialty Care: Immunology, Rare Diseases / Rare Blood Disorders, Neurology / Multiple Sclerosis, Oncology; 2nd GBU is General Medicines: Diabetes, Cardiovascular, Established Products; 3rd GBU is Vaccines: Influenza vaccines, Polio Pertussis & Hib, Boosters, Meningitis, others. There is also a standalone GBU for Consumer Healthcare: Allergy, Cough & Cold, Pain, Digestive Health, Mental Wellness. Digital is changing the healthcare landscape. Empowering patients / consumers and organising self monitoring. Digital improves patient information and product usage with sustainibility value proposition. Digital Therapeutics are opening a new way to manage pain. Sanofi Ideal partner profile has Mature technology
including mature business model. Scalable across more than 2
geographies. Compliance with cybersecurity and data protection. Sustainibility value proposition. Easy to purchase
(onsite & e-commerce). Impact on consumers includes Consumer focus. Proven improvement in health or lifestyle outcome. Data driven claims supported by scientific evidence. Augmented consumer experience. Sanofi has a partner centric philosophy.
Successfully Accessing Medical Equipment Markets in CIVETS Available on Rese...QYResearchReports
The short-lived positron-emitting isotopes used in PET imaging are generally produced in a cyclotron and then synthesised on-site before patient administration. Although not requiring the use of a nuclear reactor, this limits the use of PET imaging to centres with access to a cyclotron and synthesis equipment. Therefore, a major development is the recent availability of smaller and cheaper cyclotrons which are designed to produce C-11 and F-18 isotopes economically and on-demand, without the need for radiochemistry or PET accelerator expertise.
The 10 companies booming in healthcare sector smallinsightscare
Development is a continuous process in any sector. It brings in more comfort, more precision, and more enhanced way of living.Acknowledging the remarkable contribution of the leading companies in the care sector, we bring to you the special issue of “The 10 Companies Booming in Healthcare Sector”.
'The Digital Healthcare Leap' highlights insights into how digital health could be an answer to the emerging markets’ challenge to achieve sustainable growth; and leapfrog the developed nations to provide quality, affordable, universal and patient-centric care.
With increased internet and smartphone penetration, and the arrival of new affordable technological solutions in the market, digital healthcare will eventually become a fundamental business imperative. The challenge to healthcare providers for the future, is to adapt and set strategies that leverage new technology while putting patients at the heart of everything they do.
Healthcare as an industry is transforming. The concept of wellbeing is increasing in importance. Living environments are evolving, including smart homes, assisted living and robotics. Technologies and innovations are having major impacts to individual’s life. Individuals are taking more control and recognizing also their responsibility.
Business Finland and Future Watch commissioned a study on the landscape of developments that will impact the delivery of Health & Wellbeing, to better understand the anticipated transformations, impacts and opportunities to support its strategy for ensuring Finland is well positioned to take advantage of such trends and to help drive better decision making for all stakeholders in Finland. Results of the study are published and discussed with stakeholders and companies in Business Finland’s Smart Life Finland program webinars.
The 2019 edition of the Global Innovation Index (GII) focuses
on the theme Creating Healthy Lives—The Future of Medical
Innovation. In the years to come, medical innovations such
as artificial intelligence (AI), genomics, and mobile health
applications will transform the delivery of healthcare in both
developed and emerging nations.
The key questions addressed in this edition of the GII include:
• What is the potential impact of medical innovation on
society and economic growth, and what obstacles must
be overcome to reach that potential?
• How is the global landscape for research and development
(R&D) and medical innovation changing?
• What health challenges do future innovations need to address
and what types of breakthroughs are on the horizon?
• What are the main opportunities and obstacles to future
medical innovation and what role might new policies play?
Webinar: Digital Health Strategy: Leveraging Emerging Technologies in HealthcareIntellectsoft
WEBINAR VIDEO - https://www.intellectsoft.net/l/31/webinar-digital-healthcare
JOIN OUR WEBINAR TO:
- Explore what changed for healthcare practices and operations during COVID-19 and predict what leaders can expect in terms of recovery;
- Discover today’s featured examples of our clients’ technology solutions that can help you provide better and more efficient services;
- Discuss how to evolve and adapt for the rest of 2020 and into 2021 using emerging technologies and more efficient solutions.
BEST FOR:
- Сhief Medical Officers
- Doctors Pharmaceuticals
- HR Department Outstaffing
- Telemedicine Workers
- Insurance Companies
- Pharmacies
- Laboratories
- Private Hospitals
- Academical Health Centres
- Private Healthcare Facilities
- Management Information Systems
https://www.intellectsoft.net/
Technology is disrupting healthcare just as it has in so many other areas of life. New players and
new approaches are proliferating but while the changes may seem dazzlingly diverse there is a single, underlying driving force. Digital transformation in healthcare has many elements: health data privacy, ethical AI, IOT solutions, many brought to the market by new disruptors. These are all valuable elements of transformation, but ultimately they are steering to a single goal; empathetic care of
the empowered patient. In this increasingly patient-centric future it is the empathetic care, not the technology itself, that will prove to be the outstanding feature. The market leaders in this landscape will be those who embrace and explore its possibilities.
Living in a hyper-connected world, patients have never been so well informed or had so much decision- making power, at least when it comes to chronic diseases. Less dependent on their doctors for advice, increasingly able and willing to take greater control of their own health, they feel empowered by the vast amount of health information available online, on apps, and by the array of health and fitness wearables.
Such consumer digital empowerment is pushing rapid change in healthcare provision. Industry leaders across providers, insurers, medical technology and the pharmaceuticals industry, need to re-imagine
the traditional spectrum of sales, marketing and commercialisation processes by developing empathetic engagement tools to accompany and support the patient on their personal journey. This digital transformation imperative becomes a huge challenge because of the complexity of the industry ecosystem and the varying models in APAC.
With widely varying reimbursement and access challenges across APAC countries, coupled with diverse social and cultural norms, it is important for pharma, insurance, and healthcare providers to work together with partners who have local, real-world expertise when it comes to understanding patient behaviours. Together those partnerships can deliver solutions that will impact patient lives positively. Across APAC the opportunities are considerable with a huge growing market for medication and care, but there are also significant cultural and financial hurdles to the uptake of treatments.
Wendy Mayer, VP of Worldwide Innovation at Pfizer presented this at the Health Hackathon at Cornell Tech on April 9, 2015 to the audience of Cornell, MIT, Harvard, and Weill students. #HealthHack2015
In this report we set out ten provocative statements predicting the world of 2020. Each prediction is articulated and brought to life through a series of portraits which imagine how patients, healthcare professionals and life sciences organizations might behave in this new world. Our predictions lean more towards an optimistic view of the future, although we organized that many in our industry are organized about the constraints and therefore pace of change. We describe the big trends rolled forward to 2020 and some of the constraints that will need to be overcome.
We also provide examples and evidence, based on the here and now, that show that the predictions are perfectly plausible, perhaps inspiring and surprising!
Our industry is changing quickly – requiring a bold response that is often difficult to implement – and yet organizations struggle to understand how to respond effectively and build a sense of urgency. We hope this report creates rich dialogue and enables a move to action.– we have had enormous fun discussing these predictions and sharing our experiences. We hope you have the same experience within your own organizations as you peruse this report and reflect on your current situation and future scenarios.
The 10 Companies Booming in Healthcare Sectorinsightscare
Acknowledging the remarkable contribution of the leading companies in the care sector, we bring to you the special issue of “The 10 Companies Booming in Healthcare Sector”. This edition portrays the inspiring stories of the listed pre-eminent organizations that are shaping the future of healthcare through innovation and dedication.
Future of health - An initial perspective - Devi ShettyFuture Agenda
An initial perspective on the future of health by Dr Devi Shetty, Chairman and Founder of Narayana Health in India. This is the starting point for the global future agenda discussions taking place through 2015 as part of the the futureagenda2.0 programme. www.futureagenda.org
The ten predictions for 2020
1. Health consumers in 2020
Informed and demanding patients are now partners in their own healthcare
2. Health care delivery systems in 2020
The era of digitised medicine - new business models drive new ideas
3. Wearables and mHealth applications in 2020
Measuring quality of life not just clinical indicators
4. Big Data in 2020
Health data is pervasive – requiring new tools and provider models
5. Regulation in 2020
Regulations reflect the convergence of technology and science
6. Research and Development in 2020
The networked laboratory - partnerships and big data amidst new scrutiny
7. The pharmaceutical commercial model in 2020
Local is important but with a shift from volume to value
8. The pharmaceutical enterprise configuration - the back office in 2020
Single, global and responsible for insight enablement
9. New business models in emerging markets in 2020
Still emerging, but full of creativity for the world
10. Impact of behaviours on corporate reputation in 2020
A new dawn of trust
Mexico's connected healthcare market is projected to grow from $995.4 Mn in 2022 to $7469.23 Mn by 2030, registering a CAGR of 28.65% during the forecast period of 2022-30. The main factors driving the growth would be increasing technological adoption, the aging population, the rising prevalence of chronic diseases, and government support. To get a detailed report, contact us at - info@insights10.com
Similar to Healthcare whitepaper 20150218.pptx (20)
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
2. 4%
7%
7%
2%
Emerging markets will shape healthcare growth
…GHI delivers intelligence to win globally.
Source: Global Health Intelligence analysis based on data
from the OECD, CEPAL, WHO, the World Bank and certain
local ministries
Healthcare expenditure will grow 2 to 3x as fast in emerging markets…
3. Global Health Intelligence provides:
Hospital
demographics
The
world’s
largest
hospital
demographics
database
focused
on
emerging
markets
Medical
import
data
The
most
expansive
healthcare
equipment
import
staQsQcs
in
Mexico
Tailored
research
Refined
with
20+
years
Market
Intelligence
experience
• Market
sizing
and
segmentaQon
• Partner
search
&
market
due
diligence
• CompeQQve
profiling
• Pricing
and
cost
analysis
• Best
pracQces
• PosiQoning
and
opportunity
idenQficaQon
‚
ƒ
2
5. La/n
America’s
healthcare
market
is
evolving
in
ways
that
will
present
new
opportuni/es
for
firms
willing
to
invest
in
the
region.
The
report’s
insights
are
intended
to
enable
decision
makers
to
seize
the
right
opportuni/es
and
inform
their
go-‐to-‐market
strategies
throughout
the
region
accordingly.
This
report
outlines
4
key
themes
driving
change
in
customer
behavior
and
market
context:
1. The
aging
populaQon
2. The
prevalence
of
chronic
diseases
3. The
beginnings
of
healthcare
technology
innovaQon
4. Policy
changes
As
well
as
5
developments
in
specific
segments
of
the
healthcare
market
with
important
implicaQons
for
investors:
1. PharmaceuQcal
sales
growth
2. Predominance
of
generic
drugs
3. ConsolidaQon
of
pharmacy
retailing
4. OpportuniQes
in
the
region’s
16,000+
hospitals
5. The
appeal
of
the
medical
device
market
Forward
4
To
learn
more
about
Global
Health
Intelligence,
our
services,
consulQng
engagements
and
speaking
opportuniQes,
please
contact:
Guillaume
Corpart,
Managing
Director
+1
(305)
441-‐9300
gc@globalhealthintelligence
www.globalhealthintelligence.com
6. 9 drivers and opportunities
5
EVOLVING
CONTEXT
AND
CUSTOMERS
OPPORTUNITIES
IN
A
CHANGING
COMPETITIVE
LANDSCAPE
1.
Demographics
will
create
opportuniQes
for
the
private
sector
5.
Pharmaceu/cal
sales
will
grow
12%
per
year
through
2017
2.
Chronic
disease
prevenQon
and
treatment
will
drive
growth
in
certain
healthcare
segments
6.
Generics
will
account
for
65%
of
LaQn
America’s
retail
pharmaceuQcal
drug
sales
by
2016
3.
Technology
advancement
will
create
opportunity
for
new
market
developments
7.
The
consolida/on
of
pharmacy
retailing
will
generate
investment
opportuniQes
4.
Brazil
invites
foreign
investment
to
private
healthcare
8.
The
potenQal
of
LaQn
America’s
16,000+
hospitals
9.
Imported
medical
devices
account
for
over
$10
billion
in
LaQn
America
8. SHIFTING
DEMOGRAPHICS
LaQn
America
is
basking
in
a
2-‐to-‐3
decade
demographic
sweet
spot:
• There
is
lower
popula/on
growth,
driven
by
urbanizaQon,
greater
access
to
educaQon
and
a
larger
proporQon
of
women
in
the
workforce
• Popula/on
aged
over
65
will
rise
at
a
rate
three
Qmes
higher
than
the
growth
rate
for
the
populaQon
as
a
whole
in
2000-‐2025
This
will
shia
healthcare
needs
moving
forward
OPPORTUNITIES
1. Private
enterprise
could
play
a
greater
role
in
coping
with
increased
demand,
parQcularly
in
non-‐hospital
care
such
as
clinics,
ambulatory
services,
hospice
care,
nursing
faciliQes,
and
home
care
2. Technology,
IT
and
the
private
sector
have
opportuniQes
in
lowering
healthcare
access
costs
(especially
of
an
aging
populaQon)
in
fields
such
as
telemedicine,
healthcare
IT,
medical
devices
and
medical
technologies
3. Preven/ve
care
and
health
promoQon
are
on
the
rise,
expanding
opportuniQes
for
healthy
eaQng,
exercise
and
diets
1. Demographics will create opportunities for the private
sector
7
40%
41%
32%
23%
18%
56%
55%
62%
67%
64%
3%
4%
6%
10%
18%
1950
1975
2002
2025
2050
0-‐14
15-‐64
65+
Percentage of Latin American population by
age group, historic and forecast
Demographic
bonus
Demographic
dividend
Probability
High
Impact
Regional
Speed
Slow
9. THE
PREVALENCE
OF
CHRONIC
DISEASES
Non-‐communicable
diseases
will
be
the
cause
of
84%
of
deaths
in
La/n
America
by
2030
• Obesity
is
at
the
heart
of
the
discussion
as
it
is
a
trigger
for
condiQons
such
as
diabetes,
high
blood
pressure
and
cholesterol,
heart
disease,
strokes
and
respiratory
and
gastrointesQnal
diseases
• Cancer
is
also
on
the
rise
–
esQmates
show
that
1
million
people
will
succumb
to
cancer
annually
by
2030,
with
1.7
million
cases
diagnosed
annually
IMPLICATIONS
FOR
HEALTHCARE
1. Preven/on
is
a
vast
area
of
opportunity
for
pharmaceuQcal
companies
and
food
manufacturers
2. Improving
healthcare
access
and
the
quality
of
detec/on
methods
is
an
area
of
future
growth
for
medical
imaging
equipment
manufacturers
and
providers
of
diagnosQcs
services
and
equipment
3. The
increasing
demand
for
drugs
designed
to
treat
cancer,
diabetes
and
heart
disease
will
affect
local
and
internaQonal
laboratories
2. Chronic disease prevention and treatment will drive growth
in certain healthcare segments
8
Adult obesity in the world, as a percentage
of total population
Probability
High
Impact
Regional
Speed
Medium
2%
2%
3%
4%
14%
15%
17%
19%
19%
25%
31%
35%
India
China
Japan
Korea
Poland
Brazil
Russia
South
Africa
Turkey
Chile
Mexico
USA
10. Two
types
of
transformaQve
changes
to
modern
healthcare
could
eventually
take
LaQn
America
by
storm:
1.
EFFICIENCY
GAINS
IN
PUBLIC
HEALTHCARE
EXPENDITURE
• Telemedicine,
which
can
help
reduce
the
high
cost
of
spreading
healthcare
infrastructure
in
rural
areas,
is
a
new
area
of
growth
for
medical
equipment
manufacturers
who
supply
integrated
technology
soluQons
• “Big
data”
analysis,
which
can
yield
cost
savings,
remains
costly
and
is
not
yet
widespread
even
in
U.S.
hospitals,
yet
early
movers
may
reap
many
dividends,
especially
with
government
customers
looking
to
boost
cost
efficiencies
2.
THE
PERSONALIZATION
OF
MEDICAL
TREATMENTS
• Mobile
health
apps,
which
enable
users
to
monitor
their
health
and
manage
chronic
diseases,
are
a
growing
market
in
the
region,
where
smartphone
use
is
expected
to
double
by
2017,
accounQng
for
40%
of
the
region’s
populaQon
• 3D
prin/ng,
beginning
to
be
used
in
the
medical
technology
industry,
is
unlikely
to
disrupt
LaQn
America’s
healthcare
sector
in
the
near
future,
offering
a
longer
horizon
for
maximizing
profits
from
tradiQonal
medical
devices
sales
3. Technology advancement will create opportunity for new
market developments
9
Probability
Medium-‐Low
Impact
Brazil,
Mexico,
Colombia
Speed
Medium
11. The
Brazilian
government
announced
in
January
2015
that
it
would
allow
foreign
investment
in
the
private
healthcare
sector,
marking
a
significant
turning
point
with
broad
implica/ons
for
investment
in
the
healthcare
sector:
INCREASED
HEALTHCARE
SPENDING
• Aaer
growing
from
8.9%
of
GDP
in
2011
to
9.1%
in
2013,
healthcare
spending
is
now
projected
to
rise
to
$255.5
billion
by
2017.
FOREIGN
FIRMS
TO
PLAY
IN
THE
HOSPITAL
MARKET
• Hospitals
and
clinics,
to
be
open
to
foreign
investment
for
the
first
Qme,
have
great
potenQal
–
Brazil’s
concentrated
hospital
market
and
their
revenue
streams
make
for
rich
pickings.
PROTOCOL
STANDARDIZATION
• Foreign
investment
is
likely
to
accelerate
the
professionalizaQon
of
hospital
management
pracQces,
which
will
create
opportuniQes
for
investment
in
IT
systems,
management
skills,
and
tools
to
monitor,
control,
and
report
key
performance
indicators.
SUSTAINABILITY
OF
THE
SUS
• Investment
in
the
private
healthcare
sector
has
the
potenQal
to
shia
the
burden
away
from
the
public
healthcare
system,
the
Sistema
Único
da
Saúde
(SUS),
which
could
gradually
stabilize
the
SUS’s
long-‐term
financial
health.
4. Brazil invites foreign investment to private healthcare
10
Probability
High
Impact
Brazil
Speed
Medium-‐Fast
13. 38%
35%
24%
21%
18%
23%
12%
11%
8%
10%
$954
bi
$1,172
bi
North
America
Europe
Asia
/
Afirca
/
Australia
Japan
LaQn
America
DEFINING
DEVELOPMENTS
The
growing
middle
class
will
spend
more
on
healthcare,
as:
• An
increased
use
of
generics
will
conQnue
to
be
the
main
consumpQon
papern
• Local
producers
of
generic
drugs
are
becoming
the
driving
force
of
the
pharmaceuQcal
market
• The
consolida/on
of
pharmacies
and
the
conQnued
expansion
of
retail/supermarket
chains
will
accentuate
MARKETS
THAT
STAND
OUT
1. Brazil,
accounQng
for
43%
of
the
region’s
pharmaceuQcal
sales
between
2013-‐2017,
is
expected
to
become
the
world’s
fiah
largest
pharmaceuQcal
market
by
2016
2. Mexico
is
the
second
largest
market
in
LaQn
America
with
17%
of
the
region’s
sales
3. Colombia
and
Peru
present
strong
growth
prospects,
albeit
from
a
small
base
5. Pharmaceutical sales will grow 12% per year through 2017
12
Probability
High
Impact
Brazil,
Mexico,
Colombia,
Peru
Speed
Fast
Share of global pharmaceutical spending by
region 2013-2017
Ý
12%
Ü
3%
Ý
12%
Ü
2%
Ü
3%
CAGR
2013-‐2017
2013
2017
14. GROWTH
OF
THE
GENERIC
MARKET
As
healthcare
expenditure
grows
in
the
region,
two
market
forces
will
drive
the
growth
of
the
generic
drugs
market:
• The
expira/on
of
46
patents
in
the
U.S.
will
invite
greater
compeQQon
to
provide
low-‐cost
alternaQves
for
popular
drugs
• Governments
who
heavily
subsidize
the
health
system,
notably
Brazil,
ArgenQna
and
Colombia,
turn
to
generics
as
their
opQon
of
choice
The
use
of
generics
is
expected
to
increase
16%
per
year,
unQl
reaching
65%
of
all
drug
sales
by
2016
THE
WINNERS
1. Local
generics
manufacturers
have
been
growing
28%
per
year,
selling
generics
70%
more
economically
than
their
patented
counterparts
2. Large
pharmacy
and
retail
chains
have
leveraged
their
buying
power
and
logisQcs
networks
to
sell
greater
volumes
of
generics
at
the
expense
of
smaller
medical
distributors
and
pharmacies
$79
$86
$466
$631
$62
$234
$122
$417
$14
$40
$88
$143
$0
$300
$600
$900
$1,200
ROW
Pharmerging
markets
Developed
economies
Global
Spending
Branded
Generic
Other
$78
$58
$458
$602
$45
$111
$88
$239
$12
$25
$82
$115
$0
$300
$600
$900
$1,200
ROW
Pharmerging
markets
Developed
economies
Global
Spending
6. Generics will account for 65% of Latin America’s retail
pharmaceutical drug sales by 2016
13
Pharmaceutical spending by class of drug
and type of market, 2011 vs. 2016 forecast
Probability
High
Impact
Brazil,
Mexico,
Chile,
Colombia
Speed
Fast
15. 7. The consolidation of pharmacy retailing will generate
investment opportunities
14
Probability
High
Impact
Regional
Speed
Slow
Dominant
local
pharmacy
chains,
which
are
expanding
both
in
terms
of
geography
and
breadth
of
services,
will
become
ever
more
appealing
to
foreign
investors
–
the
sector’s
consolidaQon
and
diversificaQon
is
playing
out
in
three
ways:
1.
DIVERSIFICATION
INTO
BASIC
MEDICAL
SERVICES
The
expansion
of
low-‐cost
and,
in
some
cases,
free
medical
checkups
and
exams
onsite
within
the
premises
of
pharmacy
outlets
is
set
to
conQnue
2.
VERTICAL
INTEGRATION
OF
THE
PRODUCTION
CHAIN
Pharmacy
chains
are
venturing
into
the
producQon
of
private
label
generic
drugs,
becoming
producers
and
distributors
of
pharmaceuQcals
3.
CONSOLIDATION
OF
THE
DISTRIBUTION
CHANNELS
The
trend
of
medical
distributors
and
pharmacy
retailers
forging
Qghter
bonds
is
beginning
to
take
place
in
LaQn
America
as
well
Pharmaceutical sales in leading Latin
American countries, US$ millions
$36 $37 $38 $40 $42 $45 $49
$16 $17 $18 $19 $20 $21
$22
$2 $4 $4 $4 $5
$6
$6
$0
$20
$40
$60
$80
$100
2011 2012 2013 2014 2015 2016 2017
Brazil Mexico Colombia
16. THE SIZE OF THE OPPORTUNITY
While
hospital
spending
in
LaQn
America
lags
behind
that
of
the
U.S.
and
Europe,
the
size
of
the
opportunity
warrants
a
closer
look
–
La/n
America
is
home
to
16,000+
hospitals
TRAGETTED INVESTMENT
Analyzing
hospital
demographics
can
uncover
a
wealth
of
opportuni/es,
including:
• 50%
of
hospitals
in
Brazil
are
located
in
six
states
• 20%
of
hospitals
in
Brazil
have
over
100
beds
• 25%
of
hospitals
in
Mexico
are
located
in
three
states
• 10%
of
hospital
physicians
in
Mexico
are
pediatricians
• Amongst
other
8. The potential of Latin America’s 16,000+ hospitals
15
Probability
High
Impact
Brazil,
Mexico,
Colombia,
ArgenQna,
Peru,
Chile
Speed
Slow-‐Medium
Number of hospitals by country
5,700
6,700
3,900
2,400
1,650
1,000
420
US
Brazil
Mexico
Colombia
Argentina
Peru
Chile
17. IMPORTED
DEVICES
TRUMP
LOCAL
PRODUCTION
Most
countries
in
the
region
have
liple-‐to-‐no
local
manufacturing
of
medical
devices
or
medical
technology.
As
a
result,
most
countries
rely
on
imports,
especially
for
high-‐end,
complex
devices.
Mexico,
Brazil,
Argen/na
and
Colombia
together
account
for
more
than
75%
of
imported
devices.
TOP
MARKETS
• Brazil
is
the
region’s
largest
and
most
mature
market
for
medical
devices
–
it
accounts
for
50%
of
the
U.S.
exports
to
the
region
and
has
a
strong
domesQc
manufacturing
industry
of
its
own.
• Mexico
is
the
region’s
largest
importer.
Its
proximity
to
the
U.S.,
developed
road
systems,
integraQon
into
the
NAFTA,
and
robust
export
manufacturing
industry
make
it
a
natural
expansion
when
looking
outside
the
US.
• Beyond
the
top
four
markets
—
Brazil,
Mexico,
ArgenQna
and
Colombia
—
a
second
Qer
stands
out,
including
Chile,
Peru
and
Costa
Rica,
which
each
benefit
from
the
right
condiQons
to
make
them
apracQve
to
medical
device
suppliers
and
manufacturers.
9. Imported medical devices account for over $10 billion in
Latin America
16
Probability
High
Impact
Regional
Speed
Medium
Medical device imports by country
Mexico,
$2.9
Brazil,
$2.2
Colombia,
$.
7
ArgenQna,
$1.9
Others,
$2.7
$.
$1.
$2.
$3.
$4.
2009
2010
2011
2012
2013
2014
US$,
billions
18. www.globalhealthintelligence.com
To
learn
more
about
Global
Health
Intelligence,
our
services,
consulQng
engagements
and
speaking
opportuniQes,
please
contact:
Guillaume
Corpart,
Managing
Director
+1
(305)
441-‐9300
gc@globalhealthintelligence